A trial comparing surgery with active monitoring for low risk DCIS (LORIS)
Ductal carcinoma in situ (DCIS) is an abnormality of the milk ducts in the breast but not in any other breast tissue. DCIS accounts for approximately 20% of breast ‘cancers’ detected by breast screening. Currently, all DCIS is treated by surgery because of concerns that it may become an invasive cancer if left untreated but many experts now believe that some cases of DCIS are unlikely to ever cause any problems in the woman’s lifetime. The LORIS Trial randomises patients with low risk DCIS to standard surgery or to active monitoring with annual mammography.
For more information click here
